866-997-4948(US-Canada Toll Free)

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 118 Pages

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.

Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
3SBio Inc
Aevi Genomic Medicine Inc
Akebia Therapeutics Inc
Amgen Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
Biocad
CCM Duopharma Biotech Bhd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Dong-A Socio Holdings Co Ltd
FibroGen Inc
GlaxoSmithKline Plc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
JCR Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Myungmoon pharmaceutical Co Ltd
Novartis AG
Panacea Biotec Ltd
Pfizer Inc
PharmaEssentia Corp
PhytoHealth Corp
Pieris Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Xenetic Biosciences Inc
Zydus Cadila Healthcare Ltd
Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles
BPI-5014B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPO-018B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin zeta biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ErepoXen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erythropoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FG-2216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSA-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTZ-951 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDGN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMP-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peg-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegylated erythropoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHEP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Renal Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSS-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vadadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products
Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones
Featured News & Press Releases
May 25, 2017: FDA Advisory Committee Recommends Approval Of Pfizer's Proposed Biosimilar To Epogen/Procrit Across All Indications
May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease
Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease
Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease
Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anemia
Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia
Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients
Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)
Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Novartis AG, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *